Introduction
The EWS/FLI-1 translocation is present in the vast majority of tumors from patients aicted with Ewing's sarcoma and tumors of the Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) family. The EWS/ FLI-1 fusion results in the joining of amino-terminal sequences of the EWS gene from chromosome 22 in frame to carboxy-terminal sequences of FLI-1, a gene located on chromosome 11 (Delattre et al., 1992) . EWS belongs to a family of RNA-binding proteins possessing transcriptional activation ability (Bertolotti et al., 1998; Lessnick et al., 1995; Ohno et al., 1993 Ohno et al., , 1994 and FLI-1 is a member of the ETS family of DNAbinding proteins (Delattre et al., 1992) . The resulting EWS/FLI-1 fusion protein is a chimeric transcription factor with preserved recognition of canonical FLI-1 binding sites (Mao et al., 1994) , but enhanced transcriptional activation properties in vitro (Bailly et al., 1994; May et al., 1993b; Ohno et al., 1993) .
In NIH3T3 cells, EWS/FLI-1 expression confers growth in semi-solid medium (May et al., 1993a) and tumorigenesis in severe combined immunode®cient (SCID) mice (May et al., 1997) . Cellular transformation by EWS/FLI-1 requires the DNA-binding domain of FLI-1 (May et al., 1993a) , suggesting that EWS/ FLI-1 acts as an oncogene by dysregulating gene expression. Several distinct EWS/FLI-1 translocations have been identi®ed in tumors from patients with Ewing's sarcoma ( Figure 1) ; however, the type I and type II fusion transcripts (EWS exon seven fused with either exon six or exon ®ve of FLI-1 respectively) comprise 77 ± 85% of the cases (de Alava and Gerald, 2000; de Alava et al., 1998; Zoubek et al., 1996; Zucman et al., 1993) .
Recently, patients with tumors containing the type I EWS/FLI-1 transcript have been demonstrated to have a more favorable prognosis than those patients with tumors containing the other fusion types (de Alava et al., 1998; Zoubek et al., 1996) . The reasons for this association are unknown, but could be related to the somewhat lower transcriptional activation properties of the type I fusion compared to the type II and other less common fusion protein types (Lin et al., 1999) . EWS/ FLI-1 has been shown to alter the expression of several proteins, including manic fringe (May et al., 1997) , the src-homology 2 (SH2) domain containing protein EAT-2 (Thompson et al., 1996) , cyclin selective ubiquitin conjugase mE2-C (Arvand et al., 1998) , and the transforming growth factor (TGF)-b type II receptor (Hahm et al., 1999) . However, much remains to be understood regarding the mechanisms responsible for EWS/FLI-1 transformation in vivo.
In this study we demonstrate that ERK1 and ERK2, members of the mitogen-activated protein kinase (MAPK) family of signaling proteins, are constitutively activated in 3T3 cells expressing type I EWS/FLI-1. Furthermore, in 3T3 clones transformed by EWS/FLI-1, the degree of ERK1 and ERK2 activation is proportional to the level of EWS/FLI-1 expression. ERK1 and ERK2 are also constitutively activated in several human tumor-derived EWS/FLI-1 cell lines, but not in cells expressing a EWS/FLI-1 mutant that is defective in DNA-binding and transcriptional activation of canonical FLI-1 DNA binding sites. Blocking ERK1 and ERK2 activation using highly speci®c inhibitors of MEK1 or by co-expression of a dominant negative ras mutant signi®cantly impairs both EWS/ FLI-1-dependent ERK activation and soft agar colony growth. Interestingly, 3T3 cells expressing the type II EWS/FLI-1 fusion protein demonstrate greater constitutive ERK activation than cells expressing the type I fusion. These ®ndings represent the ®rst intracellular signaling pathway shown to be constitutively activated by EWS/FLI-1, and suggest a potential role for ERK1 and ERK2 activation in EWS/FLI-1 cellular transformation.
Results

ERK1 and ERK2 are constitutively activated in NIH3T3 cells expressing EWS/FLI-1
Recently, constitutive activation of the MAPK signaling pathway, speci®cally ERK1 (p44  MAPK and ERK2  (p42   MAPK   ) , has been demonstrated in a variety of human cancers (Gioeli et al., 1999; Hoshino et al., 1999; Mandell et al., 1998; Patton et al., 1998; SeboltLeopold et al., 1999; Sivaraman et al., 1997) . To determine whether this signaling pathway might also be activated in sarcomas of the Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) family, stable 3T3 cell lines expressing the type I (7-6) form of the chimeric fusion protein EWS/FLI-1 were examined by Western analysis using an antibody which recognizes the activated forms of both ERK1 and ERK2. 3T3-EWS/FLI-1 cells demonstrated high levels of constitutive ERK1 and ERK2 activation, similar to that observed in cells expressing the constitutively activated ras mutant G12V or the oncogene P210 BCR/ABL (Cortez et al., 1997) (Figure 2a ). 3T3 cells expressing an EWS/ FLI-1 type I mutant, EWS/FLI-1 R2L2, previously demonstrated to be defective in DNA-binding to Figure 1 Schematic representation of the EWS and FLI-1 genes. Shaded areas represent the regions of the EWS and FLI-1 genes which join to form the most common forms of the EWS/FLI-1 fusion (type I and type II). The type I and type II fusions share the same EWS gene breakpoint (large arrow), but dier in their FLI-1 breakpoints (type I, black arrow; type II, gray arrow). Small arrows depict less common EWS and FLI-1 breakpoints. The transcriptional activation (TA) domain of the EWS gene is preserved in the EWS/FLI-1 fusions, as is the FLI-1 Ets DNA binding domain (ETS/DBD) and the FLI-1 carboxy-terminal TA (cTA) domain. The amino-terminal TA (nTA) of FLI-1, which includes the pointed (PNT) domain/sterility, Ets-related, polycomb protein (SEP) region (Laudet et al., 1999) , is variably retained in the EWS/FLI-1 fusions Figure 2 The MAPK family members ERK1 and ERK2 are constitutively activated in 3T3 cells expressing EWS/FLI-1. (a) 3T3 cells transduced with retroviral vector alone (neo), EWS/FLI-1 type I (7-6), or a EWS/FLI-1 mutant defective in DNA-binding and transcriptional activation (R2L2) (Bailly et al., 1994) , were examined by Western blot using an antibody which recognizes the activated form of ERK1/2 (pERK, top); total ERK1 and ERK2 (arrows, middle); or the EWS/FLI-1 fusion protein and endogenous FLI-1 (arrows, bottom). At center, a 3T3-EWS/FLI-1 type I clone (EF-1) and control (neo) were analysed after 6 h of serum-starvation (f serum). For comparison, 3T3 cells expressing the oncogene Bcr/Abl (B/A) or a constitutively activated ras mutant (V12), and vector control (pB) 3T3 cells are shown at far right. (b) Several stable, clonal 3T3-EWS/FLI-expressing cell lines (clones 1,7,9) were examined by immunoblot as in part A during initial (left) and subsequent passages (P3, P5) in culture. Control 3T3 cells are shown at far left. (c) A 3T3 EWS/FLI-1 population (7-6) and clone (7-6#1) were analysed by anti-ERK1/2 immune complex kinase assay (upper panel) using MBP as a substrate, and compared to 3T3 cells expressing V12 ras, or control 3T3 cells (neo). The amount of immunoprecipitated ERK1 and ERK2 protein was analysed by anti-ERK1/2 immunoblot (lower panel). (d) 3T3 cells expressing wild-type (7-6) or mutant (R2L2) EWS/FLI-1 type I, a 3T3-EWS/FLI-1 clone (C1), and control (neo) 3T3 cells were analysed by an antibody which recognizes the activated form of P38 MAPK (pP38, top), total P38 MAPK (middle), or EWS/ FLI-1 (FLI-1). 3T3 cells subjected to heat-shock (+) or C6 cells treated with anisomycin (+) are shown at right as controls for P38 MAPK activation canonical ETS sites and in active nuclear localization (Bailly et al., 1994) , did not demonstrate signi®cant ERK activation. Serum deprivation of a 3T3-EWS/ FLI-1 clone had no eect on ERK activation, suggesting that EWS/FLI-1-associated ERK activation did not require a serum-dependent factor in the culture medium. Increased expression of EWS/FLI-1, observed in high-expressing 3T3-EWS/FLI-1 clones, including those readily capable of soft agar colony growth, correlated with even greater constitutive activation of ERK1 and ERK2 (Figure 2b and data not shown). Among high EWS/FLI-1-expressing clones there was some decrease in EWS/FLI-1 protein expression over serial passages in culture, which tended to plateau; however, the level of EWS/FLI-1 protein expression continued to correlate with the level of ERK activation. There was no signi®cant dierence in the total level of either ERK1 (p44 To determine whether ERK kinase activity was elevated in 3T3 cells expressing EWS/FLI-1, an anti-ERK1/2 immune complex kinase assay was performed using MBP as a substrate. Consistent with the results obtained by phospho-speci®c immunoblot, ERK-dependent kinase activity was constitutively increased in 3T3-EWS/FLI-1 cells (Figure 2c) . A 3T3-EWS/FLI-1 clone (7-6 #1) which stably expresses EWS/FLI-1 at high levels, demonstrated even greater ERK-dependent kinase activity, comparable to that observed in 3T3 cells expressing V12 ras. To assess speci®city, 3T3-EWS/FLI-1 cells were analysed by immunoblot for activation of p38 MAPK, another MAPK signaling pathway implicated in oncogenic transformation (Raitano et al., 1995; Xu et al., 1996) and cell survival (Xia et al., 1995) . Using an antibody speci®c for the activated form of P38 MAPK, 3T3 cells expressing EWS/FLI-1, including a EWS/FLI-1 clone (C1), showed no evidence of constitutive P38 MAPK activation (Figure 2d , top), despite robust expression of EWS/FLI-1 protein (Figure 2d, lower) . EWS/FLI-1 protein expression also had no eect on total P38 protein levels (Figure 2d , middle).
MEK1 inhibitors block EWS/FLI-1 associated ERK activation
ERK1 and ERK2 are activated by signal transduction pathways acting via the dual speci®city kinase MEK1 (reviewed in Schaeer and Weber, 1999) . To determine whether EWS/FLI-1 associated ERK activation occurred by a similar mechanism, well-characterized MEK1 inhibitors PD98059 (Dudley et al., 1995) and U0126 (Favata et al., 1998) were employed. 3T3-EWS/ FLI-1 cells were treated with varying concentrations of PD98059 and U0126 and activation of ERK1 and ERK2 was examined by Western blot (Figure 3 ). PD98059 signi®cantly decreased EWS/FLI-1 ERK activation at concentrations as low as 20 mM ( Figure  3) , with a maximal eect observed at 40 mM (data not shown). U0126 had an even more potent eect on EWS/FLI-1 ERK activation, decreasing ERK activation at a concentration of 10 mM to levels observed in serum-starved 3T3 cells (Figure 3, right) . As a test for speci®city, 3T3-EWS/FLI-1 cells were treated with a highly speci®c inhibitor of P38 MAPK, SB203580, which has been demonstrated to have no detectable eects on ERK1 or ERK2 activation (Cuenda et al., 1995) . As expected, 3T3-EWS/FLI-1 cells treated with SB203580 demonstrated no reduction in ERK activation. Treatment of cells with DMSO alone had no negative eect on the constitutive activation of ERK1 and ERK2 by EWS/FLI-1. Furthermore, treatment of 3T3-EWS/FLI-1 cells with PD98059, U0126, SB203580 or DMSO had no eect on the total levels of ERK1 or ERK2 protein expression. These results suggest that MEK1 activation plays an important role in the increased ERK activation observed in 3T3-EWS/FLI-1 cells.
MEK1 inhibitors severely impair EWS/FLI-1-dependent transformation of 3T3 cells in soft agar
One of the hallmarks of EWS/FLI-1 transformation is the ability of EWS/FLI-1 to render 3T3 cells capable of growth in semi-solid medium (May et al., 1993a) . To determine the biologic signi®cance of EWS/FLI-1 associated ERK activation, 3T3-EWS/FLI-1 cells were plated in soft agar containing either PD98059, U0126, or DMSO and the number of resulting colonies was scored on days 10 ± 14 (Sebolt-Leopold et al., 1999) . 3T3-EWS/FLI-1 cells plated in soft agar containing DMSO alone formed an average of 40 ± 50 soft agar clones per 1610 5 cells (Figure 4 ). The EWS/FLI-1 mutant R2L2, which is defective in DNA-binding and transcriptional activation (Bailly et al., 1994) and ERK activation (Figure 2a, upper) , formed an average of only eight soft agar colonies, despite high-level expression by immunoblot (Figure 2a, lower) . The MEK1 inhibitors PD98059 and U0126 severely impaired the ability of EWS/FLI-1 to transform 3T3 cells in soft agar, decreasing soft agar colonies formation by ®vefold and fourfold, respectively. In fact, treatment of 3T3-EWS/FLI-1 cells with MEK1 inhibitors reduced soft agar formation to the levels observed with 3T3 cells transduced with EWS/FLI-1 R2L2 or retroviral vector alone (Figure 4 , right). 3T3-EWS/FLI-1 cells plated in the P38 MAPK inhibitor SB203580 showed no signi®cant decrease in soft agar colony number, con®rming a MEK1 inhibitor-speci®c eect.
Figure 3 MEK1 inhibitors block EWS/FLI-1-dependent ERK activation. 3T3 cells expressing EWS/FLI-1 type I were treated for 30 min with the MEK1 inhibitors U0126 (UO, 10 mM) or PD98059 (PD, 20 mM), the P38 MAPK inhibitor SB203580 (SB, 6 mM), or DMSO alone, and analysed by immunoblot with an antibody that recognizes the activated forms of ERK1 and ERK2 (pERK, top), or total ERK1/2 (ERK, lower). The positions of ERK1 and ERK2 are indicated at the arrows. As a control for ERK activation, wild-type 3T3 cells were starved (NS) and then stimulated (S) with 10% fetal calf serum and analysed by immunoblot (at right)
To rule out a non-speci®c toxic eect of the MEK1 inhibitors on cellular viability or proliferation, a similar experiment was performed on EWS/FLI-1 cells growing in soft agar or liquid culture. In these experiments a 3T3 EWS/FLI-1 clone, which stably expresses EWS/FLI-1 at robust levels (Figure 2d ), was plated in equal numbers of either soft agar or regular adherent liquid culture in various concentrations of PD98059, U0126, SB203580, or DMSO. The number of colonies growing in soft agar or upon tissue culture plates were then scored on day 7 ± 8. Consistent with uniform high-level EWS/FLI-1 expression, this 3T3-EWS/FLI-1 clonal cell line was quite ecient in soft agar colony formation (Table 1) . As was observed in the 3T3-EWS/FLI-1 bulk population, both PD98059 and U0126 signi®cantly impaired EWS/FLI-1 soft agar colony formation. PD98059 decreased the number of soft agar colonies by 3.1-fold and 5-fold at concentrations of 20 and 40 mM, respectively. U0126 decreased EWS/FLI-1 soft agar colony formation by 2.9-fold at a concentration of 10 mM and 3.2-fold at a concentration of 20 mM. Plating of cells in DMSO alone, or the P38 MAPK inhibitor SB203580, had no eect on soft agar colony formation. There was no signi®cant dierence in the ability of 3T3-EWS/FLI-1 cells to form colonies in regular adherent culture in the presence of either of the MEK1 inhibitors, with an average range of 122 ± 126 colonies per plate for PD98059, 109 ± 125 colonies for U0126 and 100 ± 119 colonies for cells plated in DMSO alone. There was also no signi®cant dierence in the size of the respective colonies, or in the total cell number obtained after colonies were dispersed by trypsinization and counted (data not shown). As expected, treatment of cells with SB203580 had no eect on the number of adherent colonies, even at a concentration of 6 mM, with an average range of 114 ± 119 colonies formed per plate. These results demonstrate that MEK1 inhibitors have a speci®c inhibitory eect on the ability of EWS/FLI-1 to transformation cells in semi-solid medium.
Dominant negative ras blocks EWS/FLI-1-dependent colony growth in semi-solid medium Treatment of 3T3-EWS/FLI-1 cells with chemical inhibitors of MEK1 profoundly decreased EWS/FLI-1-dependent soft agar colony growth. As a complementary approach to inhibiting ERK1 and ERK2 activation, dominant negative (DN) H-ras (G15A ras) (Chen et al., 1994) was introduced into 3T3-EWS/ FLI-1 cells. Because stable expression of DN ras might have deleterious biologic eects, a high titer retroviral retrovirus containing G15A ras was used to transduce a 3T3 EWS/FLI-1 clone, with an average of 60 ± 75% transduction eciency (data not shown), and cells were plated in soft agar immediately upon antibiotic selection. Protein lysates prepared from these cells were also analysed by Western blot for evidence of ERK activation. Compared to 3T3-EWS/ FLI-1 cells transduced with a retroviral vector alone, expression of DN ras abrogated EWS/FLI-1-associated ERK1 and ERK2 activation, with the level of residual ERK activation comparable to that observed in parental 3T3 cells (Figure 5a ). This reduction in EWS/FLI-1 ERK activation by GA15 ras severely impaired 3T3 soft agar colony formation. 3T3-EWS/ FLI-1 cells transduced with retroviral vector alone formed an average of 124 soft agar colonies per 3.5 cm 2 plate, similar to that observed with nontransduced cells (DMSO control cells, Table 1 ), while 3T3 cells co-expressing EWS/FLI-1 and GA15 ras formed only an average of 20 soft agar colonies, a 6.2-fold reduction (Figure 5b ).
Cell lines derived from human Ewing's sarcoma tumors demonstrate constitutive ERK activation
In 3T3 cells, EWS/FLI-1 expression consistently correlated with ERK activation. To determine whether this pathway might also be activated in human-derived cells, several well-studied human EWS/FLI-1 cell lines established from Ewing's sarcoma tumors were examined for evidence of constitutive activation of ERK1 and ERK2. Because there was considerable variation in the levels of individual and total ERK1 and ERK expression among the cell lines (data not shown), lysates were normalized for total ERK1/2 protein expression, and then examined by immunoblot to assess the degree of ERK activation (Figure 6 ). The 4 MEK1 inhibitors signi®cantly impair EWS/FLI-1-dependent soft agar colony formation. NIH 3T3 cells expressing EWS/FLI-1 type I were plated in semi-solid medium containing either PD98059 (20 mM), U0126 (10 mM), SB203580 (6 mM), or DMSO alone, and colonies were scored at day 14. As a negative control, 3T3 cells transduced with retroviral vector alone (neo) or the mutant EWS/FLI-1 R2L2, which is defective in DNA-binding and transcriptional activation (Bailly et al., 1994) , are depicted at right. Error bars represent the standard error of triplicate plates from two independent experiments EWS/FLI-1 cell lines SK-ES-1 (SK/E), RD-ES (RD), and TC-32 showed the most striking ERK activation, but TC-71, LD, and others (data not shown), also demonstrated prominent activation, comparable to 3T3-EWS/FLI-1 cells (Figure 6 , left). Although normalized for total ERK1 and ERK2 protein expression, there were dierences in relative ERK1 and ERK2 expression among the EWS/FLI-1 cell lines, with TC-71 consistently demonstrating greater ERK1 than ERK2 expression, while LD showed the opposite pattern (Figure 6, bottom) . Therefore, in both 3T3 cells and human tumor-derived cell lines, EWS/FLI-1 expression is associated with constitutive activation of the MAPK signaling pathway.
3T3 cells expressing the type II EWS/FLI-1 fusion transcript demonstrate greater ERK activation than those expressing the type I fusion
The EWS/FLI-1 cell lines SK-ES-1 and RD-ES, which both express the type II fusion (Lin et al., 1999) , demonstrated particularly prominent ERK activation ERK activation by immunoblot (Figure 6 ). The type II EWS/FLI-1 fusion has recently been reported to be a more potent transcriptional activator than the type I fusion (Lin et al., 1999) . Since ERK activation required the DNA-binding and transcriptional activation functions of EWS/FLI-1 (Figure 2a) , we compared the degree of ERK activation in 3T3 cells expressing the type I or type II EWS/FLI-1 fusions. 3T3 cells stably expressing EWS/FLI-1 type II (7-5) consistently demonstrated even greater constitutive ERK activation than 3T3 cells expressing the type I (7-6) fusion (Figure 7, upper) . This eect was not explained by dierences in EWS/FLI-1 protein expression, as both fusion types were expressed at similar levels (Figure 7, lower) . Interestingly, protein expression of the EWS/FLI-1 R2L2 mutant was consistently several fold greater than either of the wild-type EWS/FLI-1 fusions, despite similar retroviral transduction eciency.
Discussion
MAPK-related signaling is important for a broad range of normal cellular functions, including proliferation, apoptosis, adhesion, and dierentiation (reviewed in Schaeer and Weber, 1999). However, the relative contribution and role of MAPK family members to these cellular processes varies considerable among the cell type and organism studied. ERK1 and ERK2 are among the ®rst and best studied of the MAPK family members, and in addition to playing a diverse role in normal cellular functions, have also recently been implicated in neoplastic transformation. Constitutive activation of either ERK1 or ERK2 has been demonstrated in several types of human cancer, including prostate (Gioeli et al., 1999) , ovarian (Patton et al., 1998) , breast (Sivaraman et al., 1997) , gliomas (Mandell et al., 1998) , colon (Sebolt-Leopold et al., Protein lysates were prepared from 3T3 cells transduced with MINV retroviral vector alone (N), MSCV/puro (P), or 3T3 cells expressing EWS/FLI-1 (EF-1) transduced with retroviral vector alone (P) or dominant negative ras (A15) and subjected to immunoblot with either pERK (top) or an antibody which recognizes both ERK1 and ERK2 (bottom). (b) A 3T3-EWS/FLI-1 clonal cell line was transduced with retroviral vector alone (puro) or a dominant negative ras-expressing retrovirus (A15 ras) and plated in semi-solid medium as described in Materials and methods. Error bars represent the standard error from triplicate plates Figure 7 3T3 cells expressing the type II EWS/FLI-1 fusion demonstrate greater ERK1 and ERK2 activation than those expressing type I. Protein lysates from 3T3 cells expressing EWS/ FLI-1 type I (7-6), EWS/FLI-1 type II (7-5), the EWS/FLI-1 type I mutant R2L2 (Bailly et al., 1994) , or 3T3 cells transduced with retroviral vector alone (neo), were analysed by immunoblot using anti-phosphorylated ERK antibody (pERK, top), anti-ERK1/2 antibody (ERK 1/2, middle), or anti-FLI-1 antibody (FLI-1, bottom). The positions of ERK1, ERK2, EWS/FLI-1 type I (I), and EWS/FLI-1 type II (II) are indicated at the arrows 1999) and others (Hoshino et al., 1999) . Recently, interference with constitutive ERK activation in a mouse colon tumor model using a highly speci®c MEK inhibitor resulted in signi®cant tumor regression, suggesting an important role for ERK activation in human neoplasia (Sebolt-Leopold et al., 1999) .
EWS/FLI-1, and the related fusion proteins EWS/ ERG (Sorensen et al., 1994; Zucman et al., 1993) , EWS/ETV1 (Jeon et al., 1995) , and others (Kaneko et al., 1996) have been implicated as the causative agents for Ewing's sarcoma, the second most common malignant bone tumor of childhood (Ries et al., 1999) . In this study we have determined that the MAP kinases ERK1 and ERK2 are constitutively activated in 3T3 cells expressing the chimeric oncogenic transcription factor EWS/FLI-1. 3T3 cell clones expressing high levels of EWS/FLI-1 demonstrated even greater levels of ERK activation, suggesting ERK activation is a consequence of EWS/FLI-1 expression. This hypothesis is further strengthened by the demonstration that the point mutant EWS/FLI-1 mutant R2L2 (Bailly et al., 1994) , which is defective in DNA-binding and nuclear localization, did not exhibit constitutive ERK activation, despite robust expression. These ®ndings suggest that ERK activation is not a non-speci®c eect of EWS/FLI-1 overexpression, but is dependent on the ability of EWS/ FLI-1 to translocate to the nucleus, bind DNA, and alter gene expression important in regulating the balance of MAPK activation in the cell. ERK activation by immunoblot also presaged an important functional role for this pathway in EWS/FLI-1 transformation. The ability of EWS/FLI-1 to render 3T3 cells competent for growth in semi-solid medium (May et al., 1993a) has implicated EWS/FLI-1 as an oncogene, and has been a useful tool in identifying the regions of EWS/FLI-1 required for cellular transformation. In this study, ERK activation correlated with the ability of EWS/FLI-1 to transform 3T3 cells in semisolid medium, as the greatest levels of both EWS/FLI-1 and ERK activation were consistently observed in those clones capable of soft agar colony growth (Figure 2b and data not shown) .
Conversely, interference with ERK activation had profound eects on the ability of EWS/FLI-1 to transform cells. Highly speci®c inhibitors of MEK1, PD98059 and U0126, signi®cantly decreased EWS/FLI-1 ERK activation by immunoblot and profoundly impaired EWS/FLI-1-dependent transformation, decreasing the number of EWS/FLI-1 soft agar colonies by up to ®vefold. As a test for speci®city, the P38 MAPK inhibitor SB203580, which did not aect ERK1 or ERK2 activation, and was not activated in 3T3-EWS/FLI-1 cells, had no eect on the ability of EWS/ FLI-1 to transform 3T3 cells in semi-solid medium. Furthermore, interference with EWS/FLI-1 ERK activation did not have a non-speci®c toxic eect on cell survival. Treatment of 3T3-EWS/FLI-1 cells with MEK1 inhibitors had no impact on adherent colony formation while exerting a profound negative impact on growth in semi-solid medium, implicating MEK1 activation as an important feature in EWS/FLI-1 transformation. These experiments also suggest that EWS/FLI-1 activates ERK1 and ERK2 by a signaling pathway at least as far upstream as MEK1. This was con®rmed by introducing dominant negative ras (G15A) into EWS/FLI-1-expressing cells. Consistent with the results obtained with the pharmacological inhibitors of MEK1, DN ras blocked EWS/FLI-1-dependent ERK activation by immunoblot, and signi®cantly impaired the ability of EWS/FLI-1 to transform 3T3 cells in soft agar. Together these ®ndings suggest that ERK activation plays an important role in the ability of EWS/FLI-1 to transform cells.
Recent reports have identi®ed several candidate genes dierentially expressed in EWS/FLI-1 cells (Arvand et al., 1998; Hahm et al., 1999; May et al., 1997; Thompson et al., 1996) . However, our study is the ®rst to demonstrate constitutive activation of a classic intracellular signal transduction pathway by EWS/FLI-1. Interestingly, cells from a mouse with a homozygous de®ciency of insulin-like growth factor (IGF) type 1 receptor have been previously shown to be defective in EWS/FLI-1-dependent soft agar colony formation (Toretsky et al., 1997) . In light of recent studies which have implicated MAPK activation as an important consequence of IGF-I-associated signaling (Kim et al., 1997; Porras et al., 1998; Swantek and Baserga, 1999) , our results suggest a possible explanation for these ®ndings. Interference with the activation of either ras or MEK1 blocked EWS/FLI-1 ERK activation; therefore, it is likely that EWS/FLI-1 alters the expression of a gene(s) which aects the normal balance of ras signaling in the cell. This could be due to either a direct consequence of EWS/FLI-1-induced gene expression, or by an indirect mechanism in which EWS/FLI-1 could in¯uence cross-talk between other signaling pathways and ras. Another possibility is that EWS/FLI-1 alters the expression or activation of phosphatases, some of which are early-response genes, thereby in¯uencing the state of MEK1 or MAPK activation. Additional experiments will need to be performed to precisely de®ne the mechanisms for EWS/ FLI-1-dependent ERK activation, but it is likely that ongoing studies to fully characterize EWS/FLI-1-induced gene expression will provide considerable insight into this process.
It is intriguing that the type II EWS/FLI-1 fusion was even more potent in ERK activation than the type I. The EWS/FLI-1 type II protein has been recently demonstrated to be a stronger transcriptional activator than the type I fusion (Lin et al., 1999) , and patients with non-type I fusions have been shown to have a worse prognosis (de Alava et al., 1998; Zoubek et al., 1996) . Examination of other non-type I EWS/FLI-1 fusion types for the degree of ERK activation will be of interest, to determine if their increased transcriptional activation properties might also be associated with stronger ERK activation, which might explain the poorer prognosis of patients with non-type I EWS/ FLI-1 fusions. Our ®ndings also provide impetus for future study to determine whether blockade of MAPK activation will be a useful therapeutic approach in patients aicted with ES/PNET.
Materials and methods
Cells and cell culture
All cell lines were grown in 5% CO 2 and all medium was supplemented with 2 mM glutamine and penicillin/streptomy-cin. Parental and EWS/FLI-1-expressing NIH3T3 cells were grown in DME high medium supplemented with 10% bovine calf serum. The Ewing's sarcoma cell lines LD, TC-31, and TC-72 were grown in RPMI with 10% heat-inactivated fetal calf serum (FCS), and were kindly provided by Lee Helman. The other Ewing's sarcoma cell lines were obtained from the American Type Tissue Collection (ATCC): SK-ES-1 was grown in McCoy's 5A modi®ed medium supplemented with 10% FCS; and RD-ES was grown in RPMI 15% FCS, and 1 mM sodium pyruvate. For the serum starvation experiments wild-type 3T3 cells, or those transduced with EWS/FLI-1 or retroviral vector alone, were washed twice in phosphate buered saline (PBS) and placed in DME medium containing only 0.5% bovine serum albumin (BSA) for 6 ± 8 h. For serum stimulation, cells were serum deprived as above and stimulated with medium containing 10% FCS for 10 ± 15 min and protein lysates were then prepared as described below.
DNA constructs
MINV/EWS/FLI-1 was created by ®rst cloning a HindIII fragment containing the entire EWS/FLI-1 type I cDNA into pCMV Tag1 (Invitrogen, Carlsbad, CA, USA). After screening for correct orientation by restriction enzyme digestion, the EWS/FLI-1 insert was liberated by digestion with BglII and SalI and inserted into BglII and SalI digested MINV (Hawley et al., 1994; Ilaria et al., 1999) . MINV/EWS/FLI-1 R2L2 was created by digestion of DEB/EWS/FLI-1 R2L2 (Bailly et al., 1994) with HindIII, blunting with T4 DNA polymerase, and isolating the cDNA by partial restriction enzyme digestion with EcoRI. The EWS/FLI-1 R2L2 cDNA was then inserted into the MINV vector digested with EcoRI and SnaBI. MSCV/puro/A15 H-Ras was created by isolating a XhoI/EcoRI fragment containing the entire A15 H-Ras cDNA from the vector pEFmyc and inserting it into MINV vector digested a XhoI and EcoRI. MINV/EWS/FLI-1 type II was created by liberating the EWS/FLI-1 type II cDNA as a XhoI/PmeI fragment from pEF7-5 (Lin et al., 1999) and cloning it into MINV digested with XhoI and SnaBI.
Retroviral transduction
Helper-virus free replication-defective retroviral supernatants were obtained by transient transfection of 293T cells with an ecotropic packaging construct (Finer et al., 1994) as previously described (Pear et al., 1993) . All 3T3-EWS/FLI-1 cell lines described in this work are stable cell lines generated by retroviral gene transfer. Brie¯y, parental or EWS/FLI-1-expressing 3T3 cells were transduced with the appropriate retroviral vector in the presence of 8 mg hexadimethrine bromide (polybrene) for 3 ± 4 h, then the medium was changed to fresh medium and the cells allowed to recover overnight. Cells were selected 24 h after retroviral transduction in either neomycin 0.7 mg/ml (absolute) or puromycin 8 mg/ml, as appropriate.
Antibodies and Western blot
Protein lysates were prepared in RIPA buer in the presence of 1 mM PMSF, 1% aprotinin (vol/vol), 1 mM sodium orthovanadate, and 25 mM sodium¯uoride, normalized by OD 595 (Bio-Rad Protein assay, Bio-Rad Laboratories, Hercules, CA, USA), resolved by 7 or 12% SDS ± PAGE, and then electrophorectically transferred to a nitrocellulose membrane. Western blot was then performed according to the manufacturers' instructions using an anti-ERK antibody (New England Biolabs, Beverly, MA, USA), an antibody recognizing the activated form of ERK1 and ERK2 (pERK, Santa Cruz Biotechnology, Santa Cruz, CA, USA), an anti-P38 antibody (Santa Cruz Biotechnology), an antibody which recognizes the activated form of P38 MAPK (New England Biolabs), or an antibody to FLI-1 which recognizes both endogenous FLI-1 and the EWS/FLI-1 fusion protein (Santa Cruz Biotechnology). The resulting immunoblot was then developed using enhanced chemi-luminescence (Amersham, Arlington Heights, IL, USA). For the Ewing's sarcoma cell lines, cell lysates were prepared and analysed by anti-ERK1/2 immunoblot. The resulting ERK1 and ERK2 bands were analysed by densitometry using NIH image software according to suggested protocols. Protein lysate samples were then normalized for total ERK1/2 levels and subjected to SDS ± PAGE and immunoblot as outlined above.
Immune complex kinase assays
For the MBP assay, protein lysates were prepared from approximately 5610 6 cells, normalized by OD 595 , and immunoprecipitated using an anti-ERK1/2 antibody (New England Biolabs). The resulting immune complexes were incubated in kinase buer (20 mM Tris pH 8.0, 10 mM MgCl 2 , 100 mM ATP, 1 mM DTT) in the presence of [g 32 P]ATP and 10 mg MBP (Sigma) for 30 min at 308C. The supernatant was then loaded onto a 15% polyacrylamide gel, resolved by SDS ± PAGE, and developed by autoradiography. To con®rm that equivalent amounts of ERK1/2 were responsible for the observed IP kinase activity, the ERK immune complexes used in the MBP assay were resolved on a 12% polyacrylamide gel, and probed by immunoblot with anti-ERK1/2 antibody.
Soft agar and adherent colony formation
For the MEK1 inhibitor assay, 3T3 cell populations expressing wild-type or mutant EWS/FLI-1, or retroviral vector alone, were plated at a density of 1610 5 cells per 3.5 cm tissue culture dish in soft agar containing PD98059 (New England Biolabs), U0126 (Promega, Madison, WI, USA), SB203580 (Calbiochem, San Diego, CA, USA), or DMSO alone. To ensure that the eect of MEK1 inhibition did not diminish with time, colony number was assessed initially at day 7, and then again on days 10 ± 14 (Sebolt- Leopold et al., 1999) , and always yielded identical results. To compare the eect of the MEK1 inhibitors on anchoragedependent and anchorage-independent growth, a 3T3-EWS/ FLI-1 clone was plated at a density of 500 cells per 3.5 cm plate in either regular tissue culture conditions or in soft agar, in the presence of inhibitor or DMSO alone, and colony number was scored on day 7. To assess the impact of dominant negative ras expression, a 3T3-EWS/FLI-1 clone was transduced with A15 H-ras retrovirus, or retroviral vector alone, selected in puromycin as described, and plated in soft agar at a density of 500 cells per plate immediately after selection was complete (generally day 4). Colonies were scored on day 14 and followed for a total of 21 days to assure that no small EWS/FLI-1/A15 ras colonies were missed at the earlier time point.
